Literature DB >> 7562261

The demedicalization of methadone maintenance.

M Rosenbaum1.   

Abstract

The institution of methadone maintenance as a treatment modality for heroin addiction in the mid-1960s was part of the growing medicalization of social problems in the United States. The definition of deviance as "sickness" rather than "badness" set the stage for America's first harm-reduction strategy. By the 1970s methadone maintenance was seen as a way to reduce drug-related crime, and federally funded programs proliferated. Accompanying methadone's phenomenal expansion was increased regulation, bureaucratization, and criticism. The early 1980s brought the Reagan era, fiscal austerity, the new "just say no" abstinence morality, and demedicalization of methadone maintenance. By the time needle-sharing was recognized as a major contributing factor in the spread of HIV, methadone had been transformed into a largely fee-for-service, short-term, begrudgingly tolerated treatment modality. Ironically, while other countries were able to use methadone to curb the spread of AIDS, the United States refused to facilitate its expansion, and in fact impeded it. To the frustration of proponents and consumers, this original harm-reduction tool, with the potential to impact the epidemic, was demedicalized and remains marginalized.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7562261     DOI: 10.1080/02791072.1995.10471683

Source DB:  PubMed          Journal:  J Psychoactive Drugs        ISSN: 0279-1072


  9 in total

Review 1.  Disciplining addictions: the bio-politics of methadone and heroin in the United States.

Authors:  P Bourgois
Journal:  Cult Med Psychiatry       Date:  2000-06

2.  Does "difficult patient" status contribute to de facto demedicalization? The case of borderline personality disorder.

Authors:  Sandra H Sulzer
Journal:  Soc Sci Med       Date:  2015-08-07       Impact factor: 4.634

3.  Examining access to addiction treatment: scheduling processes and barriers.

Authors:  Andrew Quanbeck; Anna Wheelock; James H Ford; Alice Pulvermacher; Victor Capoccia; David Gustafson
Journal:  J Subst Abuse Treat       Date:  2012-09-27

4.  A transition of power in opioid substitution treatment: Clinic managers' views on the consequences of a patient choice reform.

Authors:  Lisa Andersson
Journal:  Nordisk Alkohol Nark       Date:  2022-02-01

5.  Methadone treatment protects against HIV infection: two decades of experience in the Bronx, New York City.

Authors:  D M Hartel; E E Schoenbaum
Journal:  Public Health Rep       Date:  1998-06       Impact factor: 2.792

6.  Socio-spatial stigmatization and the contested space of addiction treatment: remapping strategies of opposition to the disorder of drugs.

Authors:  Christopher B R Smith
Journal:  Soc Sci Med       Date:  2009-11-26       Impact factor: 4.634

7.  Drug treatment outcomes for persons on waiting lists.

Authors:  JongSerl Chun; Joseph R Guydish; Ellen Silber; Alice Gleghorn
Journal:  Am J Drug Alcohol Abuse       Date:  2008       Impact factor: 3.829

8.  Accessibility of addiction treatment: results from a national survey of outpatient substance abuse treatment organizations.

Authors:  Peter D Friedmann; Stephenie C Lemon; Michael D Stein; Thomas A D'Aunno
Journal:  Health Serv Res       Date:  2003-06       Impact factor: 3.402

9.  Structural barriers in the context of opiate substitution treatment in Germany--a survey among physicians in primary care.

Authors:  Bernd Schulte; Christiane Sybille Schmidt; Olaf Kuhnigk; Ingo Schäfer; Benedikt Fischer; Heiner Wedemeyer; Jens Reimer
Journal:  Subst Abuse Treat Prev Policy       Date:  2013-07-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.